Vaginal Dryness, Irritation and Unexpected Bleeding on a GLP-1

The short version

This page is about tissue — dryness, soreness, irritation, discomfort during sex, and bleeding that arrives when you were not expecting it. It is not about libido. Desire, arousal and the drug-versus-weight-loss-versus-life confound are covered separately on GLP-1s and sex drive; infection specifically — thrush, BV, urinary tract infections and why that warning belongs to a different class of diabetes drug — is covered on yeast infections and UTIs on a GLP-1. Between them, those two pages take the parts of this subject that have a literature.

What is left is the part that does not, and it deserves saying at the top: no study has examined the vulvovaginal environment in people taking these medicines. Not the tissue, not the microbiome, not lubrication. What follows is what can be reasoned from adjacent evidence, clearly labeled as that, plus the one symptom that should not wait.

Start here: bleeding you did not expect

Everything else on this page can be discussed at your next appointment. This cannot.

Any vaginal bleeding after menopause should be assessed promptly, whatever else is going on. A systematic review and meta-analysis of 129 studies, covering 34,432 women with postmenopausal bleeding, found that around 9% of them had endometrial cancer — and that roughly 91% of endometrial cancers present with postmenopausal bleeding in the first place¹. Most women with bleeding do not have cancer. But bleeding is the symptom that catches the ones who do, which is exactly why it is not a symptom to attribute to a new prescription and monitor at home.

If you are still cycling, the picture is different but still worth reporting. A 2026 analysis in Obstetrics and Gynecology used the FDA Adverse Event Reporting System through March 2026, restricted to women aged 12 to 55, and found semaglutide carried the broadest signal profile — disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea and anovulatory cycles. Tirzepatide generated signals for intermenstrual bleeding and clots; liraglutide produced none². A spontaneous-reporting database has no denominator and cannot separate a drug from the rapid weight loss it causes, so this is a reason to mention a change, not evidence that the drug caused it. The cycle and reproductive-hormone page unpacks that study and the contraception implications in full.

Dryness and irritation: the mechanism people invoke, and how good it is

The explanation you will read everywhere is estrogen. It is the right place to look, and it is weaker than it sounds.

Vulvovaginal tissue is estrogen-dependent, and when estrogen falls the tissue thins, lubricates less and becomes more easily irritated. That cluster has a name and a graded evidence base — the genitourinary syndrome of menopause. The Fifth International Consultation on Sexual Medicine reports that at least one GSM symptom is present in somewhere between 14% and 87% of postmenopausal women depending on the population studied, with vaginal dryness and painful sex the two most commonly reported, and the whole condition anchored explicitly to the low-estrogen state rather than to desire³. That enormous prevalence range is itself informative: this is common, under-reported, and inconsistently measured.

The bridge to weight loss is real but indirect. In a randomized trial of 439 overweight and postmenopausal women followed after a year-long diet and exercise intervention, the women who maintained their weight loss showed significantly greater decreases in free estradiol and free testosterone, and greater increases in sex hormone-binding globulin, than those who did not⁴. So sustained weight loss does measurably lower circulating free estrogen in this population.

Now the caveats, which matter more than the finding:

• That trial was in postmenopausal women aged 50 to 75. It does not describe a 34-year-old losing weight on a GLP-1.
• It measured hormones in blood, not symptoms, not tissue, and not lubrication. Nobody asked those women about dryness.
• It studied diet and exercise, not this drug class.

So the chain runs: weight loss lowers free estradiol → low estrogen is what drives GSM → therefore GLP-1 weight loss might drive vulvovaginal symptoms. Each link is defensible. The chain as a whole has never been tested, and presenting it as an established mechanism would be inventing a finding.

What the labels say, which is nothing

Reading rather than remembering: the current Wegovy prescribing information on DailyMed contains no mention of vaginal dryness, vaginal irritation, vulvovaginal atrophy or candidiasis anywhere in its adverse-reaction tables or warnings⁵. That is not evidence of absence — labels record what trials counted, and no obesity trial systematically asked about vulvovaginal symptoms — but it does mean anyone citing "the label" for this is citing something that is not there.

Sorting your own symptoms

The reason to make that distinction before an appointment is practical. "My libido is down" tends to end a conversation. "Sex has become physically painful and I am dry" tends to start one, because GSM has established, graded treatment options that a clinician can offer — and those recommendations exist independently of anything to do with a GLP-1³.

Two ordinary contributors are worth ruling out first, since both travel with this drug class and neither is mysterious: reduced fluid intake, and the general dryness of mucous membranes that shows up elsewhere as a dry mouth. If everything feels dry, that is a different question from a genital one.

Where this sits on the evidence scale

That postmenopausal bleeding needs assessment: strong, and unrelated to GLP-1s. A 9% cancer yield in women with the symptom, and 91% of endometrial cancers announcing themselves this way¹. Act on it.

That GSM causes dryness and painful sex: strong. Well characterized, gradeable, treatable³.

That sustained weight loss lowers free estradiol: moderate. Randomized, measured directly — in postmenopausal women, using diet and exercise⁴.

That GLP-1s cause vulvovaginal dryness or irritation: no evidence either way. No trial has looked. The labels do not mention it⁵. The mechanism is a chain of plausible links that nobody has connected end to end. Women describe these symptoms consistently and they are not imagining them — but "consistently reported" and "shown to be caused by the drug" are different claims, and only one of them is currently available.

What would change this page: any prospective study measuring vulvovaginal symptoms — a validated GSM instrument would do — in women starting a GLP-1, with a comparator losing weight another way. It would not be a hard study to run. It has not been run.